FGFR3 and IDUA

		FGFR3	IDUA
Description		fibroblast growth factor receptor 3	alpha-L-iduronidase
Image
GO Annotations	Cellular Component	Extracellular Region Nucleus Endoplasmic Reticulum Golgi Apparatus Plasma Membrane Integral Component Of Plasma Membrane Focal Adhesion Cell Surface Transport Vesicle Receptor Complex	Coated Vesicle Lysosomal Lumen Extracellular Exosome
	Molecular Function	Protein Tyrosine Kinase Activity Transmembrane Receptor Protein Tyrosine Kinase Activity Fibroblast Growth Factor-activated Receptor Activity Protein Binding ATP Binding Fibroblast Growth Factor Binding Identical Protein Binding	L-iduronidase Activity Hydrolase Activity, Hydrolyzing O-glycosyl Compounds Signaling Receptor Binding
	Biological Process	MAPK Cascade Skeletal System Development Endochondral Ossification Chondrocyte Differentiation Endochondral Bone Growth Transmembrane Receptor Protein Tyrosine Kinase Signaling Pathway Cell-cell Signaling Multicellular Organism Development Positive Regulation Of Cell Population Proliferation Fibroblast Growth Factor Receptor Signaling Pathway Positive Regulation Of Phospholipase Activity Peptidyl-tyrosine Phosphorylation Bone Mineralization Positive Regulation Of Kinase Activity Chondrocyte Proliferation Positive Regulation Of Tyrosine Phosphorylation Of STAT Protein Positive Regulation Of MAPK Cascade Positive Regulation Of Phosphatidylinositol 3-kinase Activity Protein Autophosphorylation Negative Regulation Of Developmental Growth Bone Morphogenesis Positive Regulation Of ERK1 And ERK2 Cascade Bone Maturation Fibroblast Growth Factor Receptor Apoptotic Signaling Pathway	Disaccharide Metabolic Process Glycosaminoglycan Catabolic Process Chondroitin Sulfate Catabolic Process Dermatan Sulfate Catabolic Process Heparin Catabolic Process
Pathways		Signaling by activated point mutants of FGFR3 FGFR3 mutant receptor activation t(4;14) translocations of FGFR3 Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer	HS-GAG degradation CS/DS degradation MPS I - Hurler syndrome
Drugs		XL999 Pazopanib Ponatinib Lenvatinib Nintedanib Fostamatinib Erdafitinib Pemigatinib Selpercatinib
Diseases
GWAS		Bladder cancer ( 24163127 20972438) Blood protein levels ( 30072576) Hip circumference adjusted for BMI ( 34021172) Metabolite levels ( 23823483) Urinary bladder cancer ( 20348956)	Blood protein levels ( 30072576 29875488) Body shape index ( 34021172) Heel bone mineral density ( 30598549) Limited cutaneous systemic scleroderma ( 29293537) Lumbar spine bone mineral density ( 22504420) Mean reticulocyte volume ( 32888494) Polymyositis ( 26362759) Primary biliary cholangitis ( 26394269)
Interacting Genes		49 interacting genes: ADD1 ANOS1 ARAP1 ATF3 BORA C6orf47 CCDC17 CEP126 CHGB CTSK EPHA4 ERBB2 FGF1 FGF17 FGF18 FGF2 FGF23 FGF3 FGF4 FGF5 FGF6 FGF7 FGF8 FGF9 GMPS GPSM3 GRB2 GRK4 GTF3C1 HBZ HNRNPL IDUA IRF2BPL KRT8 NDUFS6 NECTIN1 POLA2 PTK2B RADIL RNF130 RPL8 RPS6KA3 SH2B1 SLC25A6 SMG7 SRPK2 STAT1 STAT3 STK32B	2 interacting genes: FGFR3 MPP3
Entrez ID		2261	3425
HPRD ID		00624	02016
Ensembl ID		ENSG00000068078	ENSG00000127415
Uniprot IDs		P22607 Q0IJ44	P35475
PDB IDs		1RY7 2LZL 4K33 6LVM 6PNX 7DHL	1Y24 3W81 3W82 4KGJ 4KGL 4KH2 4MJ2 4MJ4 4OBR 4OBS 6I6R 6I6X
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?